Cost and survival analysis before and after implementation of dana-farber clinical pathways for patients with stage IV non-small-Cell lung cancer

Journal of Oncology Practice

Volumn 13, Issue 4, 2017, Pages e346-e352

  Jackman, David M ^a   Zhang, Yichen ^a   Dalby, Carole ^a   Nguyen, Tom ^a   Nagle, Julia ^a   Lydon, Christine A ^a   Rabin, Michael S ^a   Mcniff, Kristen K ^a   Fraile, Belen ^a   Jacobson, Joseph O ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL OUTCOME; CLINICAL PATHWAY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DANA FARBER CLINICAL PATHWAY; DECISION SUPPORT SYSTEM; HEALTH CARE COST; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; QUASI EXPERIMENTAL STUDY; SURVIVAL ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL DECISION MAKING; CLINICAL DECISION SUPPORT SYSTEM; FEMALE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL DECISION-MAKING; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MORTALITY; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); SURVIVAL ANALYSIS;

EID: 85017605660     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2017.021741     Document Type: Conference Paper

References (10)

1. Elkin EB, Bach PB: Cancer's next frontier: Addressing high and increasing costs. JAMA 303:1086-1087, 2010.
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011.
3. Howard DH, Chernew ME, Abdelgawad T, et al: New anticancer drugs associated with large increases in costs and life expectancy. Health Aff (Millwood) 35: 1581-1587, 2016.
4. Salas-Vega S, Mossialos E: Cancer drugs provide positive value in nine countries, but the United States lags in health gains per dollar spent. Health Aff (Millwood) 35: 813-823, 2016.
5. Feinberg BA, Milligan S, Cooper J, et al: Third-party validation of observed savings from an oncology pathways program. Am J Manag Care 19:153-157, 2013.
6. Neubauer MA, Hoverman JR, Kolodziej M, et al: Cost effectiveness of evidencebased treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6:12-18, 2010.
7. Polite B, Ward JC, Cox JV, et al: A pathway through the bundle jungle. J Oncol Pract 12:504-509, 2016.
8. Shapiro M, Stevenson J, VanWagoner E, et al: Impact of a stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Celveland Clinic Taussig Cancer Institute. J Clin Oncol 33, 2015 (suppl; abstr 6609).
9. Grimshaw J, Campbell M, Eccles M, et al: Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract 17:S11-S16, 2000 (suppl 1).
10. Stuver SO, McNiff K, Fraile B, et al: Novel data sharing between a comprehensive cancer center and a private payer to better understand care at the end of life. J Pain Symptom Manage 52:161-169, 2016.